FT : Wealthy spent 32% less on art in 2023, survey finds

Wealthy spent 32% less on art in 2023, survey finds
Modern artists go on show in Manhattan; Brexit bureaucracy hits Barcelona fair; female-focused gallery to open in London

Wealthy collectors spent on average 32 per cent less on art and antiques in 2023, according to the latest Art Basel & UBS Survey of Global Collecting, published today. The report, written by Clare McAndrew of Arts Economics, compiles responses from 3,663 high net worth Individuals from 14 regions of the world, all active in the art market, and found that their average spend fell from $532,985 in 2022 to $363,905 in 2023.

While the millionaires’ wealth was found to have grown a little after a 2022 dip, the report finds that, come 2024, their allocation to art as a percentage fell for the second year in a row, from a high of 24 per cent in 2022 to 19 per cent last year and to 15 per cent in the first half of 2024.

McAndrew reports that the drop in average spend is mostly due to the buying behaviour of millennials (defined as 28-43 years old). These were high spenders in 2022, but in 2023 they more than halved their average outlay, from $864,940 to $395,000. Taking the median spend of all buyers, which removes outliers, the fall is much less stark, McAndrew notes — from $50,165 to $50,000 — as the reduced spend was experienced mostly at higher price levels. On a median basis, buyers from mainland China (numbering 300), spent more than double that of any other region across 2023 and the first half of 2024.

During the 18-month period, more than three-quarters of respondents say they had bought a painting — the most popular medium — but there are signs that prints and works on paper, as well as emerging, new and female artists, are benefiting from a more price-conscious clientele in a recalibrating market, McAndrew writes. 

For the rest of this year, the survey finds that the market’s trajectory is “not entirely clear, with mixed signals in different sectors”. There is, however, no evidence yet that the “drag on growth” at the higher end will cease, given that “the persistent backdrop of geopolitical tensions, trade fragmentation, higher-for-longer interest rates, and other region-specific issues continue to weigh on the sentiment and plans of buyers and sellers.” The full report can be read at theartmarket.artbasel.com


Paula Cooper Gallery has joined forces with developers Brookfield Properties and WatermanClark to mount a show of Claes Oldenburg and his longtime collaborator and wife, Coosje van Bruggen, in New York’s recently renovated Lever House. The exhibition, the first major Oldenburg showing since he died in 2022, will comprise approximately 20 pieces of sculptures, drawings and prints in the publicly accessible lobby and outdoor spaces of the Midtown modernist office building. The show, organised by Jacob King, runs from November 18 until autumn 2025 with the majority of works for sale, ranging from $25,000 to $6mn.

Two of Oldenburg and Van Bruggen’s large sculptures — “Architect’s Handkerchief” (1999) and the “Plantoir, Red (Mid-Scale)” (2001-2021) — will be in the outdoor plaza, while the presentation inside will emphasise their consumer product-based works, in recognition of the building’s original 1952 owners, Lever Brothers (known more widely as Unilever). These include Oldenburg’s toothpaste sculpture “Tube Supported by its Contents” (1981). “It’s an exciting project because themes of consumerism featured so strongly in Claes and Coosje’s work,” says Steve Henry, senior partner at Paula Cooper gallery. 

Lever House is no stranger to art — its previous owner Aby Rosen, co-founder of property group RFR Holding, hosted exhibitions and commissioned art for the building, which has since undergone a $100mn redevelopment.


Additional EU customs procedures in place since Brexit meant that works by three artists which were due in the booth of London’s Soho Revue gallery at Barcelona’s Swab art fair did not arrive in time for the VIP opening. “We did everything we could. Given the new legislation, I used one of the best companies to organise it, but it seems it has all got so much more complicated since Brexit,” says gallery founder India Rose James.

For the fair’s October 3 opening, in place of works by Hanne Peeraer, Anne Carney Raines and Alanna Hernandez, the gallery instead pinned printed notices reading that, despite “heroic efforts to speed things along, it seems bureaucracy has other plans,” adding that the art was available to see on the gallery’s online viewing room.

The notices at least proved a talking point — “we met loads of new collectors,” says James — and once the art did arrive, she made sales of Peeraer’s work (around £1,000 each). “I’m sure over time it will be fine, but for now, my art-world job has become about logistics and postage”. She says she is still waiting for some of the Barcelona works to come back to the UK, with the added customs bottleneck since the Frieze and Art Basel Paris fairs.


A new gallery dedicated to living female artists will open in London’s Shoreditch later this year. SLQS is named for its founder, Goldsmiths College graduate Sarah Le Quang Sang, who says there is a need “to educate collectors to look differently at the careers of female artists”. For example, she says, the art world tends to prize youth when it comes to seeking out exciting, emerging talent, “but women often start later or take a break [to have children] so their CVs don’t fit the mould. They don’t always qualify for, say, awards for artists under 40.” Le Quang Sang, whose parents are French and French-Vietnamese, will also give visibility to artists from Vietnam such as Hoa Dung Clerget and Duong Thuy Nguyen, for whom she plans an early show. 

Le Quang Sang previewed her gallery programme at this month’s Minor Attractions and Women In Art Fair events, with works by Beverley Duckworth and a sound performance by Laima Leyton at the former, and a striking showing of Damaris Athene at WIAF (Athene will get a solo show in the gallery next year, Le Quang Sang confirms.) She will open on Club Row, close to Kate MacGarry, and says “I’m starting a business in the worst of economic times, but the gallery is well-located and compact.” 

FT : Tesla is not a car company but it does a good impersonation

Tesla is not a car company but it does a good impersonation
Although its vehicles are yielding more profit, most of the $750bn carmaker’s value hangs on things that are yet to exist

Tesla’s rising profitability sets it apart among carmakers. Rivals such as Volkswagen and Stellantis have warned of a squeeze from weaker demand and rising costs. General Motors’ electric vehicles are still lossmaking. But there is another thing that sets Tesla apart: against its peers, it is barely a carmaker at all.

True, Elon Musk’s company reported $20bn of vehicle sales in the third quarter. In a pleasant surprise for investors, the cost of making them fell to an all-time low. Tesla remains a long way from the 20mn car sales target it once set for 2030, but it is on course to meet the more modest 1.8mn analysts expect this year, according to Visible Alpha. Musk said his “best guess” was that output could expand by up to 30 per cent next year.

A rising share of Tesla’s revenue and profit, though, comes from other things. One is selling carbon credits to other carmakers. That brought in $2.5bn of revenue in the past year, equivalent to about a fifth of the company’s total operating cash flow. The other is Tesla’s blossoming battery and solar panel business, growing at 52 per cent year on year, and with higher gross margins than its cars.


Look closely at Tesla’s $750bn valuation, and it starts to become clear that cars play only a bit part. Assume Musk can make 6mn vehicles by 2030, that they sell for $35,000 each and that investors value a good car business at twice its forecast revenue, the highest multiple Toyota commanded in the past couple of decades. That suggests Tesla’s car business is worth $420bn six years from now, or about $240bn today after accounting for the time value of money.

That leaves more than $500bn unaccounted for. Batteries make up a chunk of it. So might the self-driving robotaxis that Musk touted in an underwhelming live event this month. In the future, he says all the company’s vehicles will be one giant autonomous fleet. But it is hard to say what that version of Tesla is worth, since it is yet to exist, and the cost of building it is decidedly unclear.

Then there is Optimus, the humanoid robot that Musk believes could be worth at least $10tn in long-term market value — in other words, at least 13 times more than the whole of Tesla today. Is that plausible? Impossible to say. But it brings home the real point about Tesla, which is that at $750bn, it is largely an investment in Musk’s imagination. While the likes of Volvo, Volkswagen and General Motors battle to sell cars, Tesla sells chutzpah — and investors are still buying.

>>> Europe : Brokers Upgrades & Downgrades - 24th of October 2024 V2(+)

>>> Up
* Allegro Raised to Buy at Citi; PT 42 zloty
* Atlas Copco Raised to Buy at Pareto Securities; PT 200 kronor
* Atria Raised to Buy at Inderes; PT 13 euros
* Cargotec Raised to Buy at Carnegie; PT 59 euros (+)
* DBV Tech ADRs PT Raised to $7 from $5 at HC Wainwright
* De' Longhi Raised to Buy at Kepler Cheuvreux; PT 34.50 euros
* Dowlais Raised to Neutral at Citi; PT 58 pence
* Kuehne + Nagel Raised to Hold at Research Partners
* Nyfosa Raised to Buy at Kepler Cheuvreux; PT 127 kronor (+)
* SwedenCare Raised to Buy at SEB Equities; PT 52 kronor
* SwedenCare Raised to Outperform at Handelsbanken; PT 60 kronor (+)
* Tesla PT Raised to $278 from $254 at Canaccord (+)
* Tomra Raised to Buy at Jyske Bank; PT 170 kroner
* WDP Raised to Buy at KBC Securities (+)
* WithSecure Raised to Buy at Inderes; PT 1.10 euros

>>> Down
* flatexDEGIRO Cut to Hold at Hauck & Aufhaeuser; PT 15 euros (+)
* Hypoport Cut to Hold at M.M. Warburg; PT 290 euros (+)
* Impax Asset Cut to Hold at Investec; PT 396 pence
* Michelin Cut to Hold at HSBC; PT 36 euros
* L'Oreal Cut to Hold at DZ Bank; PT 380 euros
* Storebrand Cut to Hold at Nordea
* Tecan Cut to Hold at Kepler Cheuvreux; PT 260 Swiss francs (+)
* Thule Cut to Hold at Pareto Securities; PT 350 kronor
* Torm Cut to Hold at Kepler Cheuvreux; PT 218 kroner (+)

>>> Initiation
* Telefonica Deutschland Rated New Buy at First Berlin; PT 3 euros
* Mendus Rated New Buy at Pareto Securities; PT 14 kronor
* Quilter Rated New Buy at Jefferies; PT 175 pence

>>> Call
* DAX Will Underperform if Trump Wins, JPMorgan Strategists Say

FT ; Why IPOs lag as markets soar

Why IPOs lag as markets soar
It’s another lean year for equity new issues, but might there be signs of life?

Initial public offerings have long stood as the tentpole attraction of investment banking, combining financial number-crunching and flamboyant showmanship. Banks send their biggest hitters to pitch for top-line roles, investors jostle for allocations, CEOs triumphantly ring the opening bell, and the media breathlessly cover first-day trading like a Hollywood red-carpet premiere.

Today IPOs still command attention. Jumbo listings in Poland, India and Japan have grabbed the headlines in just the last couple of weeks. But IPOs seem to have lost some of their lustre. They’ve transformed from marquee events to marginal affairs — from grand festivals to county fairs, with the nagging sense that the real party is elsewhere.

Soaring markets, sluggish IPOs
As stock indices hit all-time highs, you’d expect a corresponding surge in IPOs. Instead, we’re seeing a curious disconnect. In the US, activity is picking up, but it’s a far cry from the usual buzz. IPO volumes are not just trailing behind the stimulus-fuelled bonanza of 2020-21; they’re even lagging the more normalised period of 2017-19.

It’s as if flotation candidates are slowly overcoming their stage fright, hesitantly stepping into the spotlight. Even JPMorgan CEO Jamie Dimon finds it “odd” that rising stock markets haven’t been accompanied by a commensurate increase in IPO activity

What about the AI revolution and other technological breakthroughs? Aren’t they driving a surge of listings? Not exactly, or at least not yet. Investors have pivoted from blue-sky bets to cold, hard cash flow.

Only seven technology companies have gone public in the US this year (of which three are trading below the IPO price in a market up over 20 per cent). The biggest flotation of the year has involved a cold storage Reit, and the latest market darling was an IPO of a private equity-owned aircraft maintenance firm. For all the froth in the stock market, investors seem to prefer down-to-earth investments to moonshots.

A global drought
But if Wall Street is slowly stirring from its slumber, most international exchanges remain in deep hibernation. From London to Hong Kong, São Paulo to Singapore, IPO markets range from comatose to quiet. Even Australia, despite its much-lauded superannuation pension system, has barely mustered $400mn in IPOs this year, with the standout listing being a burrito restaurant chain started by two New Yorkers.


With these meagre volumes, many international IPO markets aren’t mere backwaters; they’re fast becoming parched riverbeds, cracked and barren where once capital flowed freely. After-market liquidity remains a persistent problem. A few venues such as India and the Gulf region show signs of life, but these flickers of hope aren’t enough to reignite a global IPO bonfire. 

Moreover, these emerging markets deals can be hit-and-miss. Hyundai’s $3.3bn IPO of its India unit drew scant interest from retail punters and opened sharply lower on its debut. In Saudi Arabia, Arabian Mills’s $270mn IPO was 132 times oversubscribed and yet didn’t start trading for a month after pricing — only to open down 10 per cent. Investors crowded into the $1.6bn Warsaw IPO of retailer Zabka, only for the shares to break issue price on the second day of trading. These may be good assets, but emerging market listings are still tough nuts to crack.

China’s unexpected stimulus package offers some hope after three dismal years for IPOs, but it highlights the extent to which its markets are subject to the whims of Beijing. The recent sharp price volatility shows that much larger injections of epinephrine will be needed in any case.


Diagnosing the IPO malaise
So what’s behind this IPO sluggishness? The reasons are multi-faceted, but fundamentally the problem boils down to a lack of compelling companies on the supply side, a dearth of actively managed funds on the demand side, and well-meaning policy interventions that inadvertently made things worse.

But first there’s the lingering impact of the ultra-loose fiscal and monetary policies of 2020-21. Unprecedented stimulus allowed companies to raise private money at nosebleed valuations and pushed many to accelerate plans to go public, either through traditional IPOs or de-SPACs. Now, with many of those pandemic-era stars trading below their initial prices, investors are nursing their wounds. At the same time, some companies hesitate to go public, fearing that valuation will fall short of the levels achieved in their last private fundraising round. A “down round IPO” could also call into question the marks of the entire portfolio of their private equity backers, jeopardising their ability to raise their next fund.

That effect will wear off, as investor memories fade and private owners itch for an exit. Private equity faces mounting pressure: distributions to paid-in capital (DPIs) ratios have fallen, and a large backlog of unsold assets has piled up. Although flotations account for less than 10 per cent of exits, buyout and venture capital firms still rely on them as a credible way to cash out — if only to create price tension for other exit strategies. Now they’re running out of options.

More structurally, the boom in private capital has reshaped the IPO landscape. Changes in US law in 1996 eased state-level securities regulation, opening the floodgates for private fundraising. Combined with historically low interest rates and persistent tax bias favouring debt financing, this has made private equity more appealing than public markets. 

With access to deep pools of private capital, many founders prefer to retain control of their companies rather than face the burdens and hassles of going public. Why contend with the pressures of quarterly earnings calls and activist shareholders when private equity offers fewer (or at least more manageable) constraints? As a result, companies can stay private much longer, reducing the urgency for an IPO. Additionally, large private companies like Stripe can raise money to provide liquidity to their employee shareholders without going public, further diminishing the incentive for an IPO.

Public market investors fret that the primacy of private capital risks turning the IPO market into the financial equivalent of Filene’s Basement, the legendary Boston retail outlet that sold excess merchandise from its upscale counterpart, Filene’s department store. The worry is that much of the good stuff has been scooped up in private deals, leaving public investors to rummage through what’s left — often companies struggling to secure private funding or whose shareholders are racing for an exit. This raises the spectre of adverse selection, with private owners trying to offload unwanted inventory on to the stock market. And when companies do go public, it’s often more about insiders cashing out than raising growth capital — hardly an exciting narrative for investors.

While the prospect of staying private beckons, the regulatory load for a public company puts off some candidates. Going public means wading through thickets of red tape and running up huge costs, thanks to regulations like the 2002 Sarbanes-Oxley Act and new climate-related rules. Annual reports are longer than Russian novels. This is manna for lawyers, auditors, and consultants, but a heavy tax for listed companies. 

It hasn’t all been in one direction: the US enacted the 2012 JOBS Act and other measures to lighten the load, and overseas jurisdictions have been trying to streamline the listing process. But overall, the high cost of going public gives owners another reason to stay private for longer.

Another challenge has been the decline of broker research. Reforms like Eliot Spitzer’s early 2000s crackdown on conflicts of interest — which were largely emulated by overseas regulators — prompted banks to slash analyst coverage, especially outside the large-cap space. Fewer analysts mean less coverage, less investor interest, and a self-reinforcing cycle of declining liquidity. The situation worsened with Europe’s MIFID II directive, which decimated the research ecosystem by “unbundling” payment for research from trade execution commissions. The EU and UK have largely rescinded these rules, but as FT Alphaville explained, the damage has been done.

Then there’s the rise of passive investing and concomitant decline of stockpickers. Index funds have made it cheap and easy for investors to access markets, but drained liquidity out of IPOs. With more money flowing into passive vehicles, there’s less cash for active managers to back new listings. In London, long-only fund managers — once a force to be reckoned with — now pack a flyweight punch. Just look at National Grid’s £7bn rights issue in May, where the two lead banks ditched the long-standing practice of sub-underwriting to institutional shareholders and pocketed all the fees themselves. 

And prudential regulations have exacerbated this issue, with Solvency II discouraging European insurers from holding equities, and pension accounting rules forcing pension funds in countries like the UK to pile into bonds. Without a deep pool of fundamental investors, selling an IPO can sometimes feel like opening a restaurant in a town where everyone’s signed up for meal kits.

Size matters
While the overall IPO market struggles, investor demand for larger deals remains robust. Consolidation among asset managers and tepid market liquidity mean that investors naturally gravitate towards bigger company IPOs. These larger flotations offer the scale and liquidity that major funds crave, creating a bifurcated market where whales can still make a splash while smaller fish have to swim furiously to create a ripple.

This preference for size also explains why overseas listings can struggle to garner interest. The 1990s and 2000s saw blockbuster IPOs of state-owned giants all over the world, but the halcyon days of big privatisations are mostly over. With telecoms, energy, and financial juggernauts in private hands, there’s little left to rouse sleepy stock markets. Singaporean brokers reminisce about the humongous Singtel IPO in 1993, when retail investors lined up in Raffles Place to apply. Now they bemoan that only “one minuscule IPO” has graced their exchange in 2024.

These privatised companies had proved so appealing not only due to their profitability (often from a legacy near-monopolistic market position), but also due to their size. In that sense last week’s successful $2.3bn IPO of Tokyo Metro is a throwback to a golden era.

The US is able to birth companies that eventually grow into behemoths, but too many overseas companies lack the scale to appeal to the full waterfront of investors. So relatively few make the cut. 

As Mario Draghi noted in his recent report on competitiveness, no EU company with a €100bn market cap has been created from scratch in the last 50 years, “while all six US companies with a valuation of €1tn have been created in this period.” Size does matter, now more than ever.

One arguable exception is China, a vast market able to support numerous big companies. This explains why in politically more supportive periods, its IPOs have appealed to investors around the world. Unfortunately, the recent crackdowns on such sectors as tech and education have reminded fund managers that government action can eviscerate, if not incinerate, equity value overnight.

Unintended policy consequences
Ironically, many of the Western government policies contributing to the IPO slowdown were enacted with good intentions. The 1996 American legislation was designed to enable capital to flow across state lines. Stricter disclosure rules were implemented to increase transparency. Analyst independence was meant to protect investors. Rules on insurance and pension funds aimed to safeguard the assets of policyholders and beneficiaries. The rise of passive investing has made the stock market more accessible for the average person. Yet collectively, these developments have created an environment that’s increasingly inhospitable to new listings.

Or maybe that was the point all along. Policymakers perhaps feel more comfortable shifting fundraising to the private sphere, where sophisticated parties can fend for themselves and there’s less chance of political fallout or finger-pointing when things go wrong. It may sound perverse to impede public access to the best companies, but that is the consequence of policy choices.

A glimmer of hope?
Will the market for new flotations bounce back? Almost certainly yes, with markets at all-time highs and after two years of slow activity. There also remains a lot of interest in certain areas, such as biosciences and AI-related spaces, including power and infrastructure. Private markets are flush with cash, but public money may be cheaper to raise in some sectors.

And there will be good deals on offer for investors, perhaps because the hype has dissipated. It’s encouraging that on its third attempt to list in Frankfurt, academic publisher Springer Nature has so far traded solidly in the after-market. Tokyo Metro, an old-economy name, soared 45 per cent on its debut last week.

But it’s unlikely that IPOs will overall recapture their former glory. For those of us who grew up [sic] in the equity capital markets, it’s a deflating spectacle. Long gone are the days of deal closing parties that were so epic you couldn’t remember them the next day. Lucite deal toys, which used to be distributed to everyone involved in an IPO, are now carefully rationed like wartime food vouchers.

The IPO, once the life of the party, now finds itself nursing a drink in the corner, wondering where all the revellers have gone.

>>> Stoxx 600 Pre-Market Indications

  • Evolution (E3G1 TH) +4.8%
    • Evolution Sees FY Ebitda Margin Below 69% to 71%, Saw 69% to 71%
  • Unilever (UNVB TH) +2%
    • *UNILEVER 3Q UNDERLYING SALES +4.5%, EST. +4.25%
  • Beiersdorf (BEI TH) +1.6%
    • Beiersdorf 9M Organic Sales +6.5%
  • Volvo Car (8JO TH) +1.5%
  • Euronext (ENXB TH) +1.4%
  • Anglo American (NGLB TH) +1.2%
    • Anglo American 3Q Diamond Production Matches Estimates
  • Infineon (IFX TH) +1.1%
  • Kion (KGX TH) +1%
  • Hermes (HMI TH) +0.7%
    • *HERMES 3Q SALES AT CONSTANT FX +11.3%, EST. +10.5%
  • Continental (CON TH) -1%
    • Michelin Guidance Trimmed, Cash Flow Target Raised: Street Wrap
  • Ashtead (0LC TH) -1%
  • Stora Enso (ENUR TH) -1.1%
    • Stora Enso 3Q Adjusted Ebit Misses Estimates
  • Kering (PPX TH) -1.7%
    • Kering Warns of Lowest Annual Profit Since 2016 as Gucci Suffers
  • BE Semiconductor (BSI TH) -2.6%
    • BE Semiconductor 3Q Orders Misses Estimates
  • Dassault Systemes (DSYA TH) -3.4%
    • Dassault Systemes Cuts Guidance After Revenue, Operating Profit Disappoint

>>> TradeGate Pre-Market Indications

DAX:
  • Beiersdorf (BEI TH) +1.5%
    • Beiersdorf 9M Organic Sales +6.5%
  • Infineon (IFX TH) +1%
  • Siemens (SIE TH) -0.2%
    • Siemens Is Said in Talks to Acquire Software Group Altair
  • Continental (CON TH) -0.7%
    • Michelin Guidance Trimmed, Cash Flow Target Raised: Street Wrap
MDAX:
  • Siltronic (WAF TH) +4.6%
    • Siltronic Sees FY Ebitda Margin 24% to 26%, Est. 24.3%
SDAX:
  • Verbio SE (VBK TH) +1.7%
  • Sixt (SIX2 TH) -1%